Mithramycin A inhibits DNA methyltransferase and metastasis potential of lung cancer cells

Ruo Kai Lin, Chun Hua Hsu, Yi Ching Wang

研究成果: 雜誌貢獻文章

43 引文 (Scopus)

摘要

Abnormal CpG island hypermethylation of multiple tumor-suppressor genes (TSGs) can lead to the initiation and progression of human cancer. The cytosine of the CpG island on the promoter region is methylated by 5′-cytosine- methyltransferases (DNMTs). Pharmacologic inhibitors of CpG island methylation provide a rational approach to reactivate the TSGs in tumor cells and to restore the critical cellular pathways in cancer cells. Mithramycin A (MMA) is known to be a GC- and CG-rich DNA-binding agent. We sought to determine whether MMA could inhibit CpG island methylation and DNMT expression in lung cancer cells. We found that MMA reduced the CpG island methylation of antimetastasis TSGs, including SLIT2 and TIMP-3 genes, and was associated with the prevention of metastasis. When highly metastatic CL1-5 lung cancer cells were treated with low doses (10 nmol/l) of MMA for 14 days, they reexpressed mRNA levels for these genes. MMA also inhibited the invasion phenotypes of CL1-5 cells as indicated by its inhibition of cancer cell migration using wound-healing and transwell assays. Molecular docking of MMA onto the DNMT1 catalytic domain revealed that MMA might interact with the catalytic pocket of DNMT1. Western blots showed that DNMT1 protein levels were depleted after MMA. These data support the idea that MMA has demethylation and antimetastasis effects on lung cancer cells. This mechanism might be mediated by the interaction of MMA and DNMT1, leading to the depletion of the DNMT1 protein and the reversal of the metastasis phenotype in lung cancer cells.

原文英語
頁(從 - 到)1157-1164
頁數8
期刊Anti-Cancer Drugs
18
發行號10
DOIs
出版狀態已發佈 - 十一月 2007
對外發佈Yes

指紋

Methyltransferases
Lung Neoplasms
Neoplasm Metastasis
CpG Islands
DNA
Tumor Suppressor Genes
Methylation
Neoplasms
Tissue Inhibitor of Metalloproteinase-3
mithramycin A
Cell Migration Inhibition
Phenotype
Critical Pathways
Cytosine
Genetic Promoter Regions
Wound Healing
Genes
Catalytic Domain
Proteins
Western Blotting

ASJC Scopus subject areas

  • Pharmacology
  • Cancer Research
  • Oncology

引用此文

Mithramycin A inhibits DNA methyltransferase and metastasis potential of lung cancer cells. / Lin, Ruo Kai; Hsu, Chun Hua; Wang, Yi Ching.

於: Anti-Cancer Drugs, 卷 18, 編號 10, 11.2007, p. 1157-1164.

研究成果: 雜誌貢獻文章

Lin, Ruo Kai ; Hsu, Chun Hua ; Wang, Yi Ching. / Mithramycin A inhibits DNA methyltransferase and metastasis potential of lung cancer cells. 於: Anti-Cancer Drugs. 2007 ; 卷 18, 編號 10. 頁 1157-1164.
@article{4f168d8a1a6d47159caf9e95e80b4e91,
title = "Mithramycin A inhibits DNA methyltransferase and metastasis potential of lung cancer cells",
abstract = "Abnormal CpG island hypermethylation of multiple tumor-suppressor genes (TSGs) can lead to the initiation and progression of human cancer. The cytosine of the CpG island on the promoter region is methylated by 5′-cytosine- methyltransferases (DNMTs). Pharmacologic inhibitors of CpG island methylation provide a rational approach to reactivate the TSGs in tumor cells and to restore the critical cellular pathways in cancer cells. Mithramycin A (MMA) is known to be a GC- and CG-rich DNA-binding agent. We sought to determine whether MMA could inhibit CpG island methylation and DNMT expression in lung cancer cells. We found that MMA reduced the CpG island methylation of antimetastasis TSGs, including SLIT2 and TIMP-3 genes, and was associated with the prevention of metastasis. When highly metastatic CL1-5 lung cancer cells were treated with low doses (10 nmol/l) of MMA for 14 days, they reexpressed mRNA levels for these genes. MMA also inhibited the invasion phenotypes of CL1-5 cells as indicated by its inhibition of cancer cell migration using wound-healing and transwell assays. Molecular docking of MMA onto the DNMT1 catalytic domain revealed that MMA might interact with the catalytic pocket of DNMT1. Western blots showed that DNMT1 protein levels were depleted after MMA. These data support the idea that MMA has demethylation and antimetastasis effects on lung cancer cells. This mechanism might be mediated by the interaction of MMA and DNMT1, leading to the depletion of the DNMT1 protein and the reversal of the metastasis phenotype in lung cancer cells.",
keywords = "DNMT, Lung cancer, Metastasis, Mithramycin A",
author = "Lin, {Ruo Kai} and Hsu, {Chun Hua} and Wang, {Yi Ching}",
year = "2007",
month = "11",
doi = "10.1097/CAD.0b013e3282a215e9",
language = "English",
volume = "18",
pages = "1157--1164",
journal = "Anti-Cancer Drugs",
issn = "0959-4973",
publisher = "Lippincott Williams and Wilkins",
number = "10",

}

TY - JOUR

T1 - Mithramycin A inhibits DNA methyltransferase and metastasis potential of lung cancer cells

AU - Lin, Ruo Kai

AU - Hsu, Chun Hua

AU - Wang, Yi Ching

PY - 2007/11

Y1 - 2007/11

N2 - Abnormal CpG island hypermethylation of multiple tumor-suppressor genes (TSGs) can lead to the initiation and progression of human cancer. The cytosine of the CpG island on the promoter region is methylated by 5′-cytosine- methyltransferases (DNMTs). Pharmacologic inhibitors of CpG island methylation provide a rational approach to reactivate the TSGs in tumor cells and to restore the critical cellular pathways in cancer cells. Mithramycin A (MMA) is known to be a GC- and CG-rich DNA-binding agent. We sought to determine whether MMA could inhibit CpG island methylation and DNMT expression in lung cancer cells. We found that MMA reduced the CpG island methylation of antimetastasis TSGs, including SLIT2 and TIMP-3 genes, and was associated with the prevention of metastasis. When highly metastatic CL1-5 lung cancer cells were treated with low doses (10 nmol/l) of MMA for 14 days, they reexpressed mRNA levels for these genes. MMA also inhibited the invasion phenotypes of CL1-5 cells as indicated by its inhibition of cancer cell migration using wound-healing and transwell assays. Molecular docking of MMA onto the DNMT1 catalytic domain revealed that MMA might interact with the catalytic pocket of DNMT1. Western blots showed that DNMT1 protein levels were depleted after MMA. These data support the idea that MMA has demethylation and antimetastasis effects on lung cancer cells. This mechanism might be mediated by the interaction of MMA and DNMT1, leading to the depletion of the DNMT1 protein and the reversal of the metastasis phenotype in lung cancer cells.

AB - Abnormal CpG island hypermethylation of multiple tumor-suppressor genes (TSGs) can lead to the initiation and progression of human cancer. The cytosine of the CpG island on the promoter region is methylated by 5′-cytosine- methyltransferases (DNMTs). Pharmacologic inhibitors of CpG island methylation provide a rational approach to reactivate the TSGs in tumor cells and to restore the critical cellular pathways in cancer cells. Mithramycin A (MMA) is known to be a GC- and CG-rich DNA-binding agent. We sought to determine whether MMA could inhibit CpG island methylation and DNMT expression in lung cancer cells. We found that MMA reduced the CpG island methylation of antimetastasis TSGs, including SLIT2 and TIMP-3 genes, and was associated with the prevention of metastasis. When highly metastatic CL1-5 lung cancer cells were treated with low doses (10 nmol/l) of MMA for 14 days, they reexpressed mRNA levels for these genes. MMA also inhibited the invasion phenotypes of CL1-5 cells as indicated by its inhibition of cancer cell migration using wound-healing and transwell assays. Molecular docking of MMA onto the DNMT1 catalytic domain revealed that MMA might interact with the catalytic pocket of DNMT1. Western blots showed that DNMT1 protein levels were depleted after MMA. These data support the idea that MMA has demethylation and antimetastasis effects on lung cancer cells. This mechanism might be mediated by the interaction of MMA and DNMT1, leading to the depletion of the DNMT1 protein and the reversal of the metastasis phenotype in lung cancer cells.

KW - DNMT

KW - Lung cancer

KW - Metastasis

KW - Mithramycin A

UR - http://www.scopus.com/inward/record.url?scp=34748837820&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34748837820&partnerID=8YFLogxK

U2 - 10.1097/CAD.0b013e3282a215e9

DO - 10.1097/CAD.0b013e3282a215e9

M3 - Article

C2 - 17893516

AN - SCOPUS:34748837820

VL - 18

SP - 1157

EP - 1164

JO - Anti-Cancer Drugs

JF - Anti-Cancer Drugs

SN - 0959-4973

IS - 10

ER -